Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A ‘Hard Days Night'

E-ISSN： 1873-4286|20|24|3958-3972

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.24, 2014-05, pp. : 3958-3972

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging drugs for non-small-cell lung cancer

By Felip Enriqueta Santarpia Mariacarmela Rosell Rafael

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 3, 2007-09 ,pp. : 449-460

Informa Healthcare

Access to resources Recommend Favorite

Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer

Current Medicinal Chemistry, Vol. 19, Iss. 22, 2012-08 ,pp. : 3689-3700

Bentham Science Publishers

Access to resources Recommend Favorite

Spotlight on Gefitinib in Non-Small-Cell Lung Cancer

By Frampton James E. Easthope Stephanie E.

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 133-136

Adis International

Access to resources Recommend Favorite

Vandetanib for the treatment of non-small-cell lung cancer

By Wong Hui-li de Boer Richard H

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 14, 2011-10 ,pp. : 2271-2278

Informa Healthcare

Access to resources Recommend Favorite

Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer

Current Drug Targets, Vol. 11, Iss. 7, 2010-07 ,pp. : 851-864

Bentham Science Publishers

Access to resources Recommend Favorite